As Lilly, Innovent hit FDA rebuff, another China-made PD-1 cancer drug faces possible delaynews2022-03-30T14:06:29+00:00March 30th, 2022|Fierce Pharma|
UPDATED: Merck cuts 143 jobs at Acceleron right on heels of $11.5B buyoutnews2022-03-30T13:55:57+00:00March 30th, 2022|Fierce Pharma|
Pfizer mRNA partner BioNTech reaped €19 billion last year but warns of lower prices in 2022news2022-03-30T13:51:00+00:00March 30th, 2022|Fierce Pharma|
Pfizer mRNA partner BioNTech reaped €19B last year but warns of lower prices in 2022news2022-03-30T13:51:00+00:00March 30th, 2022|Fierce Pharma|
Teva recalls one lot of leukemia med after finding particulates in vialnews2022-03-30T12:36:17+00:00March 30th, 2022|Fierce Pharma|
Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly’s Trulicitynews2022-03-30T11:06:48+00:00March 30th, 2022|Fierce Pharma|
After FDA green lights a second COVID booster, official says another could come in the fallnews2022-03-29T19:10:16+00:00March 29th, 2022|Fierce Pharma|
Merck, Roche and J&J among pharma players weighing Russian operations amid humanitarian tightrope walknews2022-03-29T17:26:22+00:00March 29th, 2022|Fierce Pharma|
Antares, Lipocine expand testosterone therapy offerings with FDA nod for a new, oral med for hypogonadismnews2022-03-29T15:14:27+00:00March 29th, 2022|Fierce Pharma|
Amid US patent defeat for Vascepa, Amarin makes strides in EU for fish oil-derived heart drugnews2022-03-29T14:37:10+00:00March 29th, 2022|Fierce Pharma|
